Allogeneic stem cell transplantation involves stem cell donation from a healthy donor. Cord blood is the richest and most commonly used source of allogeneic stem cells for transplantation. It is used for treating various cancers like leukemia, lymphoma, and other life-threatening diseases.
Market key trends:
One of the key trends in the market is the growing number of cord blood banks worldwide. According to the World Marrow Donor Association, there were over 35 million donors registered in the banking facilities as of 2020. This is increasing demand for allogeneic stem cells from healthy donors. Another major trend is the ongoing research and development on stem cell therapies to expand their application in treating various disorders. This includes clinical trials on stem cell therapies for conditions like cerebral palsy, autism and diabetes which can further drive the market growth.
The global Allogeneic Stem Cell Transplantation Market Size is estimated to be valued at US$ 3.9 Bn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Strength: Allogeneic stem cell transplantation can treat multiple conditions such as blood cancer, genetic diseases and certain autoimmune and immunodeficiency disorders. It is highly efficacious and represents a curative option for many patients.
Weakness: It is an invasive procedure that carries risk of complications like infection, graft rejection and graft-versus-host disease. A suitable matched donor is also required which can be difficult to find.
Opportunity: Increasing prevalence of cancer and genetic diseases is boosting demand for allogeneic stem cell transplantation procedure. Growing awareness about its benefits also offers market opportunities.
Threats: Stringent regulatory framework could hamper market growth. Risks and complications associated with the procedure also threaten its adoption. Emergence of alternative non-invasive treatments presents competition.
The global allogeneic stem cell transplantation market is expected to witness high growth, exhibiting a CAGR of 7.9% over the forecast period, due to increasing prevalence of cancer and genetic diseases.
North America dominates currently due to expanding applications of allogeneic stem cell therapy in cancer treatment and tissue engineering research. Asia Pacific is expected to grow at fastest CAGR owing to improving healthcare infrastructure, rising medical tourism and increasing initiatives by market players in countries like China and India.
Key players operating in the allogeneic stem cell transplantation market are Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., MEDIPOST Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Cellular Biomedicine Group, Inc., Biosolution Co., Ltd., StemCell Technologies Inc., Caladrius Biosciences, Inc., TiGenix N.V., ViaCord, Vericel Corporation, Regen Biopharma Inc., Gamida Cell Ltd., Histogenics Corporation, BrainStorm Cell Therapeutics Inc., Lineage Cell Therapeutics, Inc.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it